SNGX Waiting To Explode SNGX等待爆发

Soligenix, Inc., (SNGX 2.78) a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase 3 clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology which is in Phase 3 clinical trial to treat oral mucositis in head and neck cancer.

Positives for stock are:

。Two potentially catalysts events expected to be released within the next one to 4 months, SGX301 and SGX942 phase 3 trails completing. Results for SGX301 and SGX942 are expected to be erased by end of Q1 and Q2 respectively. These two kind of treament treat a rare type of Non-Hodgkin's Lymphoma know as CTCL that has no current or effective drug treatment.

。A successful report on SGX301 may position the company to commercialize its first drug in a market that is estimated at a more than $250 million revenue opportunity. At this time the market cap for the stock is only about $55 million.

。Only 19.69 million shares float. Price can easily be pushed up.

。64.91% increase in insider transactions during the last 6 months, mostly buys.

。Company has no debt.

。Technically,  SNGX has been on strong up trend since december 2019. After rising from 1.5 to 3.23 (+115%) from 1/14 to 1/24, SNGX then corrected down to 2.30 and is now trading at 2.78 and has been holding above 2.6 support for 12 days. Downside correction likely has completed and is waiting for good news to explode upward.  Initial price target is previous high at 3.23 then 4 based on measured move.

。Zacks Small Cap Research has a price target of $8 on SNGX. Analysts consensus target is 4.75.

后期生物制药公司Soligenix，Inc.（SNGX 2.78）致力于在美国开发和商品化治疗罕见病的产品。它分为两个部分：生物治疗和疫苗/生物防御。 BioTherapeutics部门开发了一种光动力疗法SGX301，该疗法正在治疗皮肤T细胞淋巴瘤的3期临床试验中； SGX942是一项先天的防御调节剂技术，正在3期临床试验中治疗头颈部癌的口腔粘膜炎。

股票的正面因素是：

。预计将在未来1-4个月内发布两个潜在的触发事件，SGX301和SGX942的第三阶段试验完成。预计SGX301和SGX942的结果将分别在第一季度和第二季度末发布。这两种疗法可治疗一种罕见的非霍奇金淋巴瘤，称为CTCL，目前尚无有效的药物治疗方法。

。SGX301的成功报告可能会使公司将其第一种药物商业化，预计该市场的收入机会将超过2.5亿美元。目前，该股票的市值仅为5500万美元。

。仅有1,696万股流通。价格可以轻易被推高。

。过去6个月，内幕人士交易增加64.91％，大多数为买入。

。公司没有债务。

。从技术上讲，自2019年12月以来，SNGX一直处于强劲的上升趋势。SNGX自1/14到至1/24从1.5升至3.23（+ 115％），随后回调至2.30，目前交易于2.78，并在2.6支撑位上方保持了12天。下行修正可能已经完成，正在等待好消息向上爆发。最初的价格目标是先前的高点3.23，然后根据据技术性量度测得目标为4。

。Zacks Small Cap Research对SNGX的价格目标为8美元。分析师综合目标价为4.75.